ライフサイエンスコーパス: prostaglandin

1 ocyclic lactones consisting of units of this prostaglandin.

2 nociceptive signaling molecule families, the prostaglandins.

3 ich is dependent on guanylyl cyclase but not prostaglandins.

4 ds to increased levels of the cyclopentenone prostaglandin 15-deoxy-Delta(12,14)-prostaglandin-J(2) t

5 The role of prostaglandin A2 (PGA2) in modulation of vascular endoth

6 Moreover, we show that prostaglandin activity is required downstream of the tra

7 induction and the consequent rise of derived prostaglandins against IRI.

8 sphosphonate and a bone activating synthetic prostaglandin agonist.

9 differ between patients receiving a topical prostaglandin analog (latanoprost) or placebo eye drops

10 rwent a procedure initially (13.5%); topical prostaglandin analogs (n = 2887/5120 [56.4%]) and laser

11 Tafluprost, a prostaglandin analogue which lowers the IOP, has shown t

12 of the efficacy and tolerability of generic prostaglandin analogues (PGAs) compared with their origi

13 out IOP change was detected among individual prostaglandin analogues in patients on monotherapy.

14 AA play a critical role in the catalysis of prostaglandin and thromboxane synthesis.

15 oncoding dsRNA as an upstream coordinator of prostaglandin and Wnt levels in regeneration.

16 to Escherichia coli, produce either abundant prostaglandins and leukotrienes (M1) or SPMs (M2).

17 olism of arachidonic acid to proinflammatory prostaglandins and leukotrienes by targeting cyclooxygen

18 ERD, correlating with enhanced production of prostaglandins and leukotrienes.

19 Prostaglandins and their receptors have been implicated

20 pid mediators (for example, leukotrienes and prostaglandins) and specialized pro-resolving lipid medi

21 is changing our understanding of eicosanoid, prostaglandin, and PL biology in health and disease.

22 regulated processes by which eicosanoids or prostaglandins are attached to phospholipids (PLs) in im

23 mbogenic nature of heparinized biomaterials, prostaglandin biomaterials, and block copolymer systems.

24 Thus, IRE1alpha-XBP1 is a mediator of prostaglandin biosynthesis and a potential target to con

25 rleukin(IL)-1beta treatment markedly induced prostaglandin biosynthesis in diseased compared to healt

26 OX-1 and -2), catalyze the committed step in prostaglandin biosynthesis-the conversion of arachidonic

27 Aspirin not only blocks the biosynthesis of prostaglandins, but also stimulates the endogenous produ

28 s cyclopentenone metabolites [cyclopentenone prostaglandins (CyPGs)], Delta(12)prostaglandin J(2) and

29 e report that depletion of endogenous L-type prostaglandin D synthase (L-PGDS) in HeLa cells inhibite

30 cyclooxygenase)-2 and L-PGDS (lipocalin-type prostaglandin D synthase) expression, which appeared to

31 Sigma class GST (Prostaglandin D synthase), FhGST-S1, is present in the e

32 ich inhibit cyclooxygenases or hematopoietic prostaglandin D synthase, respectively, or use of Crth2

33 Current research suggests that the prostaglandin D(2) (PGD(2) ) receptor 2 (DP(2) ) is a pr

34 DS) in HeLa cells inhibited recycling of the prostaglandin D(2) (PGD(2)) DP1 receptor (DP1) to the ce

35 (CRTH2), a receptor for the bioactive lipid prostaglandin D(2) (PGD(2)).

36 Prostaglandin D(2) and CXCL12 levels in BAL fluid correl

37 while triggering prostanoid (thromboxane and prostaglandin D(2) and E(2) ) production.

38 Prostaglandin D(2) and its cyclopentenone metabolites [c

39 Urinary prostaglandin D(2) and thromboxane metabolites decreased

40 obese human arteries with FTO inhibitors or prostaglandin D(2) application.

41 activation of Crth2 by 13,14-dihydro-15-keto-prostaglandin D(2) increased Ca(2+) influx through store

42 tion of L-Pgds with significant increases in prostaglandin D(2) levels.

43 or increases in urinary leukotriene E(4) and prostaglandin D(2) metabolite levels during aspirin-indu

44 duced increases in urinary leukotriene E(4), prostaglandin D(2) metabolite, or thromboxane B(2) level

45 igh-fat diet; conversely, direct addition of prostaglandin D(2) rescued myogenic tone in high-fat die

46 ot, confocal microscopy, cell degranulation, prostaglandin D(2) secretion, and proteases gene transcr

47 /2 inhibitor flurbiprofen, the hematopoietic prostaglandin D(2) synthase (HPGDS) inhibitor KMN698, an

48 Blockade of prostaglandin D(2) synthesis inhibited the myogenic tone

49 allergy (such as cysteinyl leukotrienes and prostaglandin D(2)) and the neurotransmitter acetylcholi

50 ells stimulated the synthesis and release of prostaglandin D(2), to our knowledge a previously unrepo

51 at Ptgds encodes the enzyme that synthesizes prostaglandin D2 (PGD(2)), we further explored its role

52 activation, including abundant production of prostaglandin D2 (PGD2).

53 GB001 is an oral antagonist of the prostaglandin D2 receptor that may inhibit recruitment a

54 ed lipocalin, galectin-3, and lipocalin-like prostaglandin D2 synthase with an MRA.

55 ls, along with increased production of IL-5, prostaglandin D2, and eosinophil and T-helper type 2 cel

56 ed in combination with niacin to abolish the prostaglandin D2-(PGD2)-induced flushing.

57 his effect was mediated by an increase in 15-prostaglandin dehydrogenase (15-Pgdh) activity, which ox

58 sed tendon cells, we also found increased 15-Prostaglandin Dehydrogenase (15-PGDH) expression as well

59 15-Prostaglandin dehydrogenase (15-PGDH) is the key enzyme

60 to the nucleus for repression of 15-hydroxy prostaglandin dehydrogenase (15-PGDH).

61 ric oxide (NO) and guanylyl cyclase, but not prostaglandin dependent.

62 aspirin decreased nasal symptoms and urinary prostaglandin E metabolite (P < 0.05) and increased urin

63 oup was accompanied by a decrease in urinary prostaglandin E metabolite levels (-27% +/- 7%; p = 0.01

64 Although prostaglandin E receptor (EP)-2 and EP4 for PGE2 are cou

65 ersus a combination of inflammation (PTGER2 [prostaglandin E receptor 2] and IL-6) plus growth/repair

66 trated that cyclooxygenase-2 (COX-2) and the prostaglandin E receptor, prostanoid E receptor subtype

67 Results show that only prostaglandin E receptor-4 (EP4) was involved and mediat

68 Prostaglandin E receptor-4 receptor mediates endothelial

69 ether PPI treatment affects NOX5, microsomal prostaglandin E synthase (mPGES)-1 and inducible nitric

70 in-endoperoxide synthase 2 (Ptgs2/Cox-2) and prostaglandin E synthase (Ptges/mPGES-1) was compromised

71 Finally, reduced prostaglandin E synthase 2 (PGES2) levels were found in

72 PTGES, which encodes the prostaglandin E synthase, has also been linked to asthma

73 Inhibiting COX-2 or microsomal prostaglandin E synthase-1 suppressed the 6-OHDA-trigger

74 m of COX-1 that synthesizes PgE2 (microsomal prostaglandin E synthase-1) depends critically for its v

75 RNAi knockdown of microsomal prostaglandin E synthase-1, the rate-limiting enzyme in

76 A special regulatory role for prostaglandin E(2) (PGE(2) ) has been postulated in nons

77 Furthermore, measurement of prostaglandin E(2) (PGE(2) ) levels in plasma from patie

78 -catenin signaling, cyclooxygenase-2 (COX-2)/prostaglandin E(2) (PGE(2) ) signaling, and the apeliner

79 adult human lung fibroblasts, but found that prostaglandin E(2) (PGE(2)) and fibroblast growth factor

80 Both prostaglandin E(2) (PGE(2)) and hypoxia-inducible factor

81 Reduced levels of prostaglandin E(2) (PGE(2)) contribute to aspirin-induce

82 europlasticity manifested as prolongation of prostaglandin E(2) (PGE(2)) hyperalgesia.

83 of fentanyl and confirmed by prolongation of prostaglandin E(2) (PGE(2)) hyperalgesia.

84 ndin dehydrogenase (HPGD), which catabolizes prostaglandin E(2) (PGE(2)) into the metabolite 15-keto

85 Elevated prostaglandin E(2) (PGE(2)) levels are observed in color

86 5a) during MCC fate choice, where modulating prostaglandin E(2) (PGE(2)) levels rescued MCC number.

87 trate that MDV infection activates the COX-2/prostaglandin E(2) (PGE(2)) pathway, as evident by incre

88 Prostaglandin E(2) (PGE(2)) promotes colorectal tumor fo

89 g monocytes and macrophages, which can cause prostaglandin E(2) (PGE(2)) release and consequently und

90 ulation-specific changes in sensitization by prostaglandin E(2) (PGE(2)) were observed, when compared

91 Receptors for leukotriene B(4) (LTB(4)), prostaglandin E(2) (PGE(2)), and SPMs are expressed on l

92 xpression of inflammatory mediators, such as prostaglandin E(2) (PGE(2)), bradykinin (BK), and nerve

93 sphoprotein (p-VASP) by isoproterenol (ISO), prostaglandin E(2) (PGE(2)), or forskolin (FSK) as well

94 tumorigenicity of GSCs through production of prostaglandin E(2) (PGE(2)), which stimulates beta-caten

95 xyprostaglandin dehydrogenase (15-PGDH), the prostaglandin E(2) (PGE(2))-degrading enzyme, as a hallm

96 oid 2-arachidonoylglycerol (2-AG) to produce prostaglandin E(2) (PGE(2))-glycerol (PGE(2)-G); PGE(2)-

97 process arachidonic acid into highly labile prostaglandin E(2) (PGE(2)).

98 so called COX2) to increase the synthesis of prostaglandin E(2) (PGE2) by mast cells, which activates

99 , we hypothesized that inhibiting microsomal prostaglandin E(2) (PGE2) synthase-1 (mPGES-1), the enzy

100 iators, like tumor necrosis factor-alpha and prostaglandin E(2) , increased by LPS-induced EP, were d

101 ts confirmed that silencing of MGL decreases prostaglandin E(2) accumulation in the intestine and up-

102 Pharmacological blockade of prostaglandin E(2) biosythesis favors CD103(+) dendritic

103 e outcome of drug-induced ICD and pose COX-2/prostaglandin E(2) blockade as a strategy to harness ICD

104 R4 AS-ODN) prevented OIH and prolongation of prostaglandin E(2) hyperalgesia (priming) induced by LDM

105 mice, and this was associated with decreased prostaglandin E(2) in plasma and skin.

106 cell carcinoma, ASA reduced plasma and skin prostaglandin E(2) levels and indices of UVB-induced DNA

107 nts in MCs triggered to migration by IL-8 or prostaglandin E(2) or to FcepsilonRI-stimulated secretio

108 ion, which is caused by reduced hypothalamic prostaglandin E(2) production and increased heat loss in

109 t and concentration-dependent suppression of prostaglandin E(2) production.

110 glandin F receptor activated with U46619 and prostaglandin E(2) receptor subtype 3 activated with ilo

111 activation of prostaglandin F receptors and prostaglandin E(2) receptors as well as thromboxane rece

112 ies reveal gemcitabine concurrently triggers prostaglandin E(2) release as an inhibitory DAMP to coun

113 IL-1beta treatment induced profound prostaglandin E(2) release in AR compared with AT cells.

114 plication of MGO together with bradykinin or prostaglandin E(2) resulted in an overadditive effect on

115 ase 4D (PDE4D) activity to amplify autocrine prostaglandin E(2) signaling in airway smooth muscle cel

116 and an aberrant dependency on COX-1-derived prostaglandin E(2) to maintain a tenuous homeostasis.

117 eries of small-molecule full agonists of the prostaglandin E(2) type 4 (EP(4)) receptor have been gen

118 ule sensing, a competitive FP immunoassay of Prostaglandin E(2) was demonstrated using the developed

119 CRs agonists, including thrombin, histamine, prostaglandin E(2), and ADP, stimulated robust p38 autop

120 ake of arachidonic acid and the synthesis of prostaglandin E(2).

121 daptation might be dependent on TGF-beta and prostaglandin E(2).

122 tation and host fitness through TGF-beta and prostaglandin E(2).

123 Using a connectivity map, we identified prostaglandin E1 (PGE1) as a small molecule that partly

124 h and bone density (P <0.01), enhanced 7-day prostaglandin E2 (P <0.01), and reduced 28-day inflammat

125 regnancy, including the initiation of labor, prostaglandin E2 (PGE(2)) and prostaglandin F2alpha (PGF

126 The inflammatory prostaglandin E2 (PGE(2)) EP2 receptor is a master suppr

127 algesia induced by the inflammatory mediator prostaglandin E2 (PGE(2)) in male and female rats.

128 Prostaglandin E2 (PGE(2)) is produced in the airway duri

129 glandins, including the pro-algesic mediator prostaglandin E2 (PGE(2)), was decreased in myeloid cell

130 Mechanistically, tumor-derived prostaglandin E2 (PGE2) acted selectively on EP2 and EP4

131 Prostaglandin E2 (PGE2) disrupts TGFbeta signaling and s

132 cell activation via producing high level of prostaglandin E2 (PGE2) due to their thousands-fold high

133 Prostaglandin E2 (PGE2) has emerged as a principal media

134 sing activities, we found that tumor-derived prostaglandin E2 (PGE2) induces nuclear accumulation of

135 Prostaglandin E2 (PGE2) is a lipid mediator of inflammat

136 Here we show that Prostaglandin E2 (PGE2) is an inflammatory cytokine that

137 n strongly linked to adhesion formation, and Prostaglandin E2 (PGE2) is associated with both adhesion

138 Prostaglandin E2 (PGE2) is associated with proliferation

139 Prostaglandin E2 (PGE2) is derived from arachidonic acid

140 vitalization of the cyclooxygenase (COX) and prostaglandin E2 (PGE2) pathway.

141 We tested the hypothesis that astrocytic prostaglandin E2 (PgE2) plays a key role for cerebrovasc

142 endothelial cells, we demonstrate that local prostaglandin E2 (PGE2) production in deep brain areas,

143 expression, whereas increased production of prostaglandin E2 (PGE2) promotes the differentiation of

144 The EP4 subtype of prostaglandin E2 (PGE2) receptors (EP4-R) is a particula

145 ge (0.57-fold Nrf-2 and 0.34-fold HO-1), and prostaglandin E2 (PGE2) release was increased in samples

146 Here we found prostaglandin E2 (PGE2) secreted by osteoblastic cells a

147 pithelial cell culture system, we found that prostaglandin E2 (PGE2) signaling through one of its rec

148 Prostaglandin E2 (PGE2) stimulates HSC renewal and engra

149 TLR4 ligand, induces macrophages to generate prostaglandin E2 (PGE2) through inducible COX-2 and micr

150 Fever occurs upon binding of prostaglandin E2 (PGE2) to EP3 receptors in the median p

151 nthesis and receptor pathways for eicosanoid prostaglandin E2 (PGE2) were more highly induced in IL-1

152 looxygenases (COXs) and their final product, prostaglandin E2 (PGE2), are known to play important rol

153 Previously, we revealed that prostaglandin E2 (PGE2), released during hypercapnic cha

154 at the key products of NOS2 and COX2, NO and prostaglandin E2 (PGE2), respectively, promote feed-forw

155 Human amnion fibroblasts produce abundant prostaglandin E2 (PGE2), which plays a crucial role in p

156 Among these is prostaglandin E2 (PGE2), which, in addition to its role

157 ted macrophages and expressed high levels of prostaglandin E2 (PGE2)-forming enzymes microsomal PGE2

158 iety of lipid signaling molecules, including prostaglandin E2 (PGE2).

159 -2) pathway and the concomitant increases in prostaglandin E2 (PGE2).

160 ll production of the COX-2 synthetic product prostaglandin E2 (PGE2).

161 a result of autonomic responses triggered by prostaglandin E2 action on EP3 receptors expressed by ne

162 n were performed and included measurement of prostaglandin E2 and cytosolic phospholipase A2 activity

163 isruption of the protein's ability to induce prostaglandin E2 and cytosolic phospholipase A2 synthesi

164 tion initiating mediators leukotriene B4 and prostaglandin E2 and pro-resolving mediators resolvin D1

165 COX2 is critical for the secretion of prostaglandin E2 and was strongly induced by H(2)O(2) or

166 We show that COX-2 and prostaglandin E2 are required for C1P-mediated increases

167 ia-synapse cross talk requires production of prostaglandin E2 by microglia, leading to the activation

168 , increased free water reabsorption, urinary prostaglandin E2 excretion, and reduced excretion of ser

169 Prostaglandin E2 level was significantly increased in CS

170 Urinary metabolite of prostaglandin E2 may be able to identify patients who co

171 DON-induced cyclooxygenase-2 expression and prostaglandin E2 production and pro-inflammatory cytokin

172 PGE(2) acted via prostaglandin E2 receptor 2 (EP(2)) and EP(4) to induce

173 els of acquired AI resistance indicated that prostaglandin E2 receptor 4 (PTGER4) is upregulated afte

174 resistance protein 4, and G-protein-coupled prostaglandin E2 receptors 1 and 2), abolished P-glycopr

175 Increased cyclooxygenase-2 expression and prostaglandin E2 release could be abrogated in metastati

176 g components in the cyclooxygenase-2 (COX-2)/prostaglandin E2 signaling cascade (phospholipase A2, CO

177 Even in vitro, NRF2 activation or prostaglandin E2 supplementation blunted the induction o

178 Microsomal prostaglandin E2 synthase-1 (mPGES-1) is known as an ide

179 also been linked to asthma, where deficient prostaglandin E2 synthesis has been associated with airw

180 sion induced by inflammatory pain depends on prostaglandin E2 that is synthesized by cyclooxygenase 2

181 erinatal lethal with reduced brain levels of prostaglandin E2 The non-functional phospholipase A2-act

182 reversed hyperalgesia induced by intrathecal prostaglandin E2 To distinguish between a peripheral/spi

183 We also evaluated prostaglandin E2 urinary metabolite (PGE-M) in an indepe

184 the patients with low urinary metabolite of prostaglandin E2 who received celecoxib (HR = 1.57; 95%

185 Also, PGE(2) (prostaglandin E2) added to differentiating MM6 cells up-

186 induced by diverse pronociceptive mediators, prostaglandin E2, epinephrine, TNFalpha, and interleukin

187 Elevation of baseline urinary metabolite of prostaglandin E2, indicating activation of the COX-2 pat

188 Thus, the glyceryl ester of prostaglandin E2, PGE2-G, mobilizes Ca(2+) and activates

189 s activators of PKA, including adenosine and prostaglandin E2, results in a profound delay of neutrop

190 DUSP2 led to overproduction of COX-2-derived prostaglandin E2, which promoted cancer stemness via the

191 ide lipase (ATGL) activity in neutrophils in prostaglandin E2-dependent and -independent manners.

192 ction of proinflammatory effectors including prostaglandin E2.

193 genesis and involves FGF receptor-3 (FGFR3), prostaglandin-E2 and interaction between estrogen recept

194 Prostaglandin endoperoxide H synthases-1 and -2, commonl

195 mega-6 fatty acid called arachidonic acid to prostaglandin endoperoxide H(2) (PGH(2)).

196 thesis-the conversion of arachidonic acid to prostaglandin endoperoxide H(2) Both COX isoforms are se

197 nase, ephrin-A receptor 2 (EPHA2), regulates prostaglandin endoperoxide synthase 2 (PTGS2) (encodes C

198 pithelium and included IL-1 receptor like 1, prostaglandin-endoperoxide synthase 1, CCL26, and perios

199 cyclooxygenase 2 (COX-2) gene, also known as prostaglandin-endoperoxide synthase 2 ( PTGS2), occurs i

200 s, such as histamine and proteases, activate prostaglandin-endoperoxide synthase 2 (also called COX2)

201 rowth/differentiation factor 15 (GDF15), and Prostaglandin-endoperoxide synthase 2 (PTGS2) genes, pre

202 We found that induction of prostaglandin-endoperoxide synthase 2 (Ptgs2/Cox-2) and

203 Prostaglandin-endoperoxide synthase-2 inhibition increas

204 We previously identified activation of prostaglandin EP2 receptors as a driver of undesirable c

205 y by cyclooxygenase-2-mediated activation of prostaglandin EP2 receptors.

206 ls were inhibited by activating G(s)-coupled prostaglandin-EP2 and G(q)-coupled bradykinin B2 (BK2) r

207 Galpha(z) is coupled to the prostaglandin EP3 receptor in pancreatic beta cells.

208 Activation of prostaglandin EP4 receptor attenuates the induction of c

209 and proven anabolic selective agonist of the prostaglandin EP4 receptor, compound 5, and alendronic a

210 ction of structurally diverse molecules, the prostaglandins exhibit a wide range of biological proper

211 The human prostaglandin F receptor (hFP-R) is widely expressed in

212 ivity was not limited to TP receptor because prostaglandin F receptor activated with U46619 and prost

213 We found that agonist-mediated activation of prostaglandin F receptors and prostaglandin E(2) recepto

214 Most research examined urinary 8-iso-prostaglandin F(2alpha) (8-iso-PGF(2alpha)) as the oxida

215 To clarify this, the 8-iso-PGF(2alpha)/prostaglandin F(2alpha) ratio approach was used to quant

216 signaling and also reduces expression of the prostaglandin F2a receptor negative regulator (PTGFRN),

217 tion of labor, prostaglandin E2 (PGE(2)) and prostaglandin F2alpha (PGF(2alpha)), are enzymatically d

218 inflammation-initiating mediators including prostaglandin F2alpha and leukotriene B4 and pro-resolvi

219 used to develop allosteric modulators of the prostaglandin F2alpha receptor.

220 inflammation-initiating mediators (including prostaglandin F2alpha) and select proresolving pathways

221 t aggregate inhibitor and two members of the prostaglandin family of compounds by catalytic cross-met

222 perfused; or a conventional approach with a prostaglandin flush.

223 th a mechanism downstream of proinflammatory prostaglandin formation, acetaminophen also reversed hyp

224 clooxygenase-2 catalyses the biosynthesis of prostaglandins from arachidonic acid but also the biosyn

225 hate, L-carnitine, L-aspartate, glutathione, prostaglandin G2, alpha-linolenic acid and linoleic acid

226 rachidonic acid but also the biosynthesis of prostaglandin glycerol esters (PG-Gs) from 2-arachidonoy

227 On EVLP, the BACS and prostaglandin groups showed lower pulmonary vascular res

228 n the presence of U46619, a stable analog of prostaglandin H(2) Half-maximal effective potential (V(0

229 so observed enhanced autocrine production of prostaglandin I2 (PGI2, also called prostacyclin) in Cav

230 arry out the first step in the production of prostaglandins, important mediators of inflammation, pai

231 Crus I; and (3) increased dorsal hippocampus prostaglandins in males only.

232 Inducible biosynthesis of prostaglandins, including the pro-algesic mediator prost

233 investigate the role of 15-deoxy-Delta12,14-prostaglandin J(2) (15d-PGJ(2)) in vitro.

234 Among them are Delta(12)-prostaglandin J(2) (Delta(12)-PGJ(2)) and Delta(12)-pros

235 opentenone prostaglandins (CyPGs)], Delta(12)prostaglandin J(2) and 15-deoxy-Delta(12,14)-prostagland

236 prostaglandin J(2) and 15-deoxy-Delta(12,14)-prostaglandin J(2), act through 2 GPCRs, d-type prostano

237 landin J(2) (Delta(12)-PGJ(2)) and Delta(12)-prostaglandin J(3) (Delta(12)-PGJ(3)), whose unusual str

238 entenone prostaglandin 15-deoxy-Delta(12,14)-prostaglandin-J(2) that can activate the NLPR3 inflammas

239 oduct of inflammation, 15-deoxy-Delta(12,14)-prostaglandin J2 (15-d-PGJ2), triggers eIF2alpha phospho

240 15-deoxy-Delta(12,14)-prostaglandin J2 (15d-PGJ2) is naturally produced in the

241 Increased production of prostaglandin J2 (PGJ2) activates peroxisome proliferato

242 epoxy-eicsatrienoic acid, and 15-deoxy-12,14-prostaglandin J2 as most predictive.

243 azone, troglitazone, and 15-deoxy-Delta12,14-prostaglandin J2) decrease levels of beta-catenin.

244 8:1 fatty acids; increases in lipoxin A4 and prostaglandin J2; and a decrease in 20-hydroxyeicosatetr

245 , in colonic tumors contributes to increased prostaglandin levels and poor patient survival.

246 We also uncovered higher prostaglandin metabolic gene expression in the tumor, re

247 We evaluated changes in leukotriene and prostaglandin metabolites for NIUA patients, using patie

248 anti-progesterone drug mifepristone and the prostaglandin misoprostol can be used to treat missed mi

249 Analysis of components of the prostaglandin pathway revealed upregulation of multiple

250 To delineate the Cox-independent prostaglandin pathways and evaluate their role in sperm

251 utic effect superior to global inhibition of prostaglandin (PG) biosynthesis by aspirin-like drugs.

252 old), cysteinyl leukotrienes (4.5-fold), and prostaglandin (PG) D(2) (5.4-fold), as well as PGE(2) (6

253 The prostaglandin (PG) D(2)-chemoattractant receptor-homolog

254 It is unknown whether microsomal (m) prostaglandin (PG) E synthase (S)-1, a target downstream

255 Prostaglandin (PG) E(2) exhibits antifibrotic properties

256 is known to mediate the protective effect of prostaglandin (PG) E(2) in the gastrointestinal tract; h

257 in temperature (Tsk) analysis, assessment of prostaglandin (PG) E(2) levels (the proximal mediator of

258 isoproterenol, epinephrine, norepinephrine, prostaglandin (PG) E(2), PGD(2), and adenosine strongly

259 Prostaglandin (PG) E2 is a bioactive lipid that plays pr

260 otypes were distinguished by thromboxane B2, prostaglandin (PG) E2, and PGD2 production, in addition

261 in vitro: for example, formation of TxA(2) , prostaglandin (PG) F(2alpha) , 11-hydroxyeicosatraenoic

262 C3) catalyzes the synthesis of 9alpha,11beta-prostaglandin (PG) F(2alpha) and PGF(2alpha) prostanoids

263 re comparable in tumors from both genotypes, prostaglandin (PG) levels were higher in the PyMT(Delta2

264 ntiality is largely due to their function as prostaglandin (PG) precursors.

265 idespread reduction (between 50% and 90%) in prostaglandin (PG) profiles in fish tissues and plasma w

266 Aspirin (acetylsalicylic acid) inhibits prostaglandin (PG) synthesis by transfer of its acetyl g

267 ass spectrometry identified this compound as prostaglandin (PG)E2.

268 IR ), and synthesis of nitric oxide (NO) and prostaglandins (PG).

269 -derived eicosanoids (leukotriene [LT] C(4), prostaglandin [PG] D(2), and thromboxane A(2)), which me

270 The messenger RNA encodes the prostaglandin PGD(2) synthesizing enzyme.

271 icosanoid profile of reduced proinflammatory prostaglandins (PGE(2) and TXB(2)) and an increased abun

272 ice responded more robustly to another major prostaglandin, PGE(2), than did male mice.

273 Prostaglandins (PGs) have critical signaling functions i

274 Similar to OT, prostaglandins (PGs) play key roles in myometrial contra

275 The contribution of prostaglandins (PGs) to exercise hyperaemia is controver

276 While prostaglandins (PGs), short-range lipid signals, regulat

277 elegans synthesizes Cox-independent F-series prostaglandins (PGs).

278 he effects of nicotinic acid indicating that prostaglandins play a key role in mediating the sleep an

279 proinflammatory cytokine known to stimulate prostaglandin production and EP3 expression.

280 Endogenous G(s)-coupled prostaglandin receptors stimulated PRG binding to membra

281 ry rate-based statistics identified a higher prostaglandin reductase 2 expression at early reperfusio

282 ), an enzyme involved in production of these prostaglandins, results in delayed parturition in mice.

283 negative regulator (PTGFRN), an inhibitor of prostaglandin signaling and follicle-stimulating hormone

284 ny in the zebrafish embryo kidney, and found prostaglandin signaling is essential both for renal MCC

285 The discovery that prostaglandin signaling mediates renal MCC development h

286 his appears to be a consequence of excessive prostaglandin signaling.

287 Prostaglandins stimulate uterine contractions and are cl

288 of transcripts encoding enzymes involved in prostaglandin synthesis and metabolism.

289 ENT By using mice with selective deletion of prostaglandin synthesis in brain endothelial cells, we d

290 long-term objective of specific targeting of prostaglandin synthesis in prevention of preterm birth.

291 Inhibition of prostaglandin synthesis may provide a novel treatment fo

292 and significant upregulation (p < 0.0001) of prostaglandin-synthesising enzymes on brain tissue.

293 ivity of aspirin-acetylated COX-2 forms 15 R-prostaglandins that inhibit platelet aggregation.

294 hough proinflammatory eicosanoids, including prostaglandins, thromboxanes, and leukotrienes, are crit

295 dothelium-derived hyperpolarizing factor, or prostaglandins to cause vasodilation.

296 t through its downstream derivatives such as prostaglandins, to activate Akt and inhibit cisplatin-in

297 n with a variant in SLCO2A1, which encodes a prostaglandin transporter in the distal nephron.

298 Therefore, we predicted that inhibiting the prostaglandin transporter SLCO2A1 may selectively kill c

299 Prostaglandin use and previous retinal detachment were n

300 tion, particularly through the generation of prostaglandins via the cyclooxygenase system.